The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases

Simple item page
buir.contributor.authorTemirci, Elif Sena
buir.contributor.authorJavad, Osama
dc.citation.epage674en_US
dc.citation.issueNumber2en_US
dc.citation.spage661en_US
dc.citation.volumeNumber49en_US
dc.contributor.authorTürk, Canen_US
dc.contributor.authorOkay, M.en_US
dc.contributor.authorTürk, S.en_US
dc.contributor.authorTemirci, Elif Senaen_US
dc.contributor.authorJavad, Osamaen_US
dc.contributor.authorAksu, S.en_US
dc.contributor.authorSayınalp, N.en_US
dc.contributor.authorHaznedaroğlu, İ. C.en_US
dc.date.accessioned2020-02-24T08:00:53Z
dc.date.available2020-02-24T08:00:53Z
dc.date.issued2019-04
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractBackground/aim: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinibinduced JAK/STAT pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas. However, the biological basis and significance of this pharmacobiological adverse event is unknown. The aim of this bioinformatics study is to detect any possible confounding effects of ruxolitinib on the genesis of lymphoproliferative disorders. Materials and methods: The gene expression data were retrieved from the E-MTAB-783 Cancer Genome Project database. Gene expression data for all available genes in 26 cell lines belonging to various types of lymphomas were chosen for use in this in silico analysis. Results: We identified genes that were significant in developing resistance to ruxolitinib in lymphoma cell lines. Conclusion: Based on the results of our present study, ruxolitinib may potentially lead to the pathological expression of the transcription factors important in lymphoma genesis, neoplastic commitment on the progenitor lymphoid cells, inhibition of repressor transcriptions protective for lymphoma development, inhibition of apoptosis, promotion of neoplastic proliferation, transcriptional activation, and proliferation of malignant neoplastic B cells.en_US
dc.identifier.doi10.3906/sag-1807-152en_US
dc.identifier.issn1300-0144
dc.identifier.urihttp://hdl.handle.net/11693/53478
dc.language.isoEnglishen_US
dc.publisherTÜBİTAKen_US
dc.relation.isversionofhttps://dx.doi.org/10.3906/sag-1807-152en_US
dc.source.titleTurkish Journal of Medical Sciencesen_US
dc.subjectLymphomaen_US
dc.subjectRuxolitiniben_US
dc.subjectJAK/STAT signaling pathwayen_US
dc.titleThe impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseasesen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The_impact_of_JAK_STAT_inhibitor_ruxolitinib_on_the_genesis_of_lymphoproliferative_diseases.pdf
Size:
2.92 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Department of Molecular Biology and Genetics